LP
Laxman Prasad Shukla
About Laxman Prasad Shukla
Data last updated:
Laxman Prasad Shukla has 21 years in corporate governance. Holds Managing Director and Director roles. Currently with 4 companies, including Bion Therapeutics (India) Private Limited and Biondia Therapeutics Private Limited. Formerly with 2 companies, such as Lakshya Lifescience Private Limited and Sri Sai Infra Projects India Private Limited. Engaged in General Business, Healthcare.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
| Managing Director | 05 Sep 2005 | 2005 | Active | |
| Managing Director | 28 Apr 2010 | 2010 | Active | |
| Director | 15 May 2015 | 2015 | Active | |
| Director | 06 Dec 2025 | 2025 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
| Director | 21 Sep 2021 | 2021 | Active | |
| Director | 02 Aug 2019 | 2019 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Laxman Prasad Shukla
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Laxman Prasad Shukla
Laxman Prasad Shukla has 21 years in corporate governance. Holds Managing Director and Director roles. Currently with 4 companies, including Bion Therapeutics (India) Private Limited and Biondia Therapeutics Private Limited. Formerly with 2 companies, such as Lakshya Lifescience Private Limited and Sri Sai Infra Projects India Private Limited. Engaged in General Business, Healthcare.
Laxman Prasad Shukla is associated with 4 companies as Managing Director and Director.
Laxman Prasad Shukla has expertise in General Business, Healthcare.
Laxman Prasad Shukla has 21 years in corporate governance.